Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer. Irene Knuesel brings longstanding experience in CNS research, drug discovery and development. She is also a founder of Scienza Consulting GmbH, an independent science consultancy company. Among others, she brings six years of experience in the definition and implementation of discovery strategies in neuroimmunology and neurodegeneration with F. Hoffmann-La Roche, where in her last position as Head, Neuroimmunology and Neurodegeneration Section, she was responsible for 11 research lab heads focusing on neuroimmune and neurodegenerative mechanisms underlying disease and disability progression in multiple sclerosis, Alzheimer’s…